PMID- 27104186
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160422
LR  - 20210102
IS  - 2287-979X (Print)
IS  - 2288-0011 (Electronic)
IS  - 2287-979X (Linking)
VI  - 51
IP  - 1
DP  - 2016 Mar
TI  - Recent advances in haploidentical hematopoietic stem cell transplantation using 
      ex vivo T cell-depleted graft in children and adolescents.
PG  - 8-16
LID - 10.5045/br.2016.51.1.8 [doi]
AB  - Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment 
      for children and adolescents with various malignant and non-malignant diseases. 
      While human leukocyte antigen (HLA)-identical sibling donor is the preferred 
      choice, matched unrelated volunteer donor is another realistic option for 
      successful HSCT. Unfortunately, it is not always possible to find a HLA-matched 
      donor for patients requiring HSCT, leading to a considerable number of deaths of 
      patients without undergoing transplantation. Alternatively, allogeneic HSCT from 
      haploidentical family members could provide donors for virtually all patients who 
      need HSCT. Although the early attempts at allogeneic HSCT from haploidentical 
      family donor (HFD) were disappointing, recent advances in the effective ex vivo 
      depletion of T cells or unmanipulated in vivo regulation of T cells, better 
      supportive care, and optimal conditioning regimens have significantly improved 
      the outcomes of haploidentical HSCT. The ex vivo techniques used to remove T 
      cells have evolved from the selection of CD34(+) hematopoietic stem cell 
      progenitors to the depletion of CD3(+) cells, and more recently to the depletion 
      of alphabeta(+) T cells. The recent emerging evidence for ex vivo T cell-depleted 
      haploidentical HSCT has provided additional therapeutic options for pediatric 
      patients with diseases curable by HSCT but has not found a suitable related or 
      unrelated donor. This review discusses recent advances in haploidentical HSCT, 
      focusing on transplant using ex vivo T cell-depleted grafts. In addition, our 
      experiences with this novel approach for the treatment of pediatric patients with 
      malignant and non-malignant diseases are described.
FAU - Im, Ho Joon
AU  - Im HJ
AD  - Department of Pediatrics, University of Ulsan College of Medicine, Asan Medical 
      Center Children's Hospital, Seoul, Korea.
FAU - Koh, Kyung-Nam
AU  - Koh KN
AD  - Department of Pediatrics, University of Ulsan College of Medicine, Asan Medical 
      Center Children's Hospital, Seoul, Korea.
FAU - Seo, Jong Jin
AU  - Seo JJ
AD  - Department of Pediatrics, University of Ulsan College of Medicine, Asan Medical 
      Center Children's Hospital, Seoul, Korea.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160325
PL  - Switzerland
TA  - Blood Res
JT  - Blood research
JID - 101605247
PMC - PMC4828537
OTO - NOTNLM
OT  - Hematopoietic stem cell transplantation
OT  - adolescents
OT  - children
OT  - ex vivo T cell depletion
OT  - haploidentical
EDAT- 2016/04/23 06:00
MHDA- 2016/04/23 06:01
PMCR- 2016/03/01
CRDT- 2016/04/23 06:00
PHST- 2016/02/29 00:00 [received]
PHST- 2016/03/11 00:00 [revised]
PHST- 2016/03/16 00:00 [accepted]
PHST- 2016/04/23 06:00 [entrez]
PHST- 2016/04/23 06:00 [pubmed]
PHST- 2016/04/23 06:01 [medline]
PHST- 2016/03/01 00:00 [pmc-release]
AID - 10.5045/br.2016.51.1.8 [doi]
PST - ppublish
SO  - Blood Res. 2016 Mar;51(1):8-16. doi: 10.5045/br.2016.51.1.8. Epub 2016 Mar 25.